These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36653850)
1. Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments. Meijuan C; Meng X; Fang L; Qian W J Ovarian Res; 2023 Jan; 16(1):16. PubMed ID: 36653850 [TBL] [Abstract][Full Text] [Related]
2. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma. Tao Y; Liang B Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917 [TBL] [Abstract][Full Text] [Related]
3. TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer. Yang Q; Yu B; Sun J Biomed Res Int; 2020; 2020():4625123. PubMed ID: 33282948 [TBL] [Abstract][Full Text] [Related]
4. Hypomethylated gene RAC3 induces cell proliferation and invasion by increasing FASN expression in endometrial cancer. Meijuan C; Fang L; Min F; Qian W Int J Biochem Cell Biol; 2022 Sep; 150():106274. PubMed ID: 35917927 [TBL] [Abstract][Full Text] [Related]
5. Identification of Zhu Y; Lin X; Zang Y; Yang Q J Healthc Eng; 2021; 2021():4372373. PubMed ID: 34970423 [TBL] [Abstract][Full Text] [Related]
6. BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity. Liu J; Tian T; Liu X; Cui Z J Immunol Res; 2022; 2022():6051092. PubMed ID: 35915658 [TBL] [Abstract][Full Text] [Related]
7. Identification of aberrantly methylated differentially expressed genes and associated pathways in endometrial cancer using integrated bioinformatic analysis. Liu J; Wan Y; Li S; Qiu H; Jiang Y; Ma X; Zhou S; Cheng W Cancer Med; 2020 May; 9(10):3522-3536. PubMed ID: 32170852 [TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Five-immune Gene Pair Signature in Endometrial Carcinoma. Li N; Yu K; Lin Z; Zeng D Comb Chem High Throughput Screen; 2021; 24(2):233-245. PubMed ID: 32729416 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis. Yang L; Cui Y; Sun X; Wang Y Aging (Albany NY); 2021 Jan; 13(3):4564-4589. PubMed ID: 33495413 [TBL] [Abstract][Full Text] [Related]
10. High expression of the ferroptosis-associated MGST1 gene in relation to poor outcome and maladjusted immune cell infiltration in uterine corpus endometrial carcinoma. Yan J; Ye G; Shao Y J Clin Lab Anal; 2022 Apr; 36(4):e24317. PubMed ID: 35218676 [TBL] [Abstract][Full Text] [Related]
11. Significance analysis of PAX8 expression in endometrial carcinoma. Hu S; Gan H; Yang F Medicine (Baltimore); 2022 Oct; 101(42):e31159. PubMed ID: 36281161 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value and Immune-Infiltration Pattern of Yang Z; Shen X; Luo S; Li Y Dis Markers; 2022; 2022():9621701. PubMed ID: 35126794 [TBL] [Abstract][Full Text] [Related]
13. Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma. Cheng P; Ma J; Zheng X; Zhou C; Chen X Sci Rep; 2021 Jun; 11(1):12608. PubMed ID: 34131259 [TBL] [Abstract][Full Text] [Related]
14. Increased FOXM1 Expression was Associated with the Prognosis and the Recruitment of Neutrophils in Endometrial Cancer. Chen J; Yang P; Li S; Feng Y J Immunol Res; 2023; 2023():5437526. PubMed ID: 37159818 [TBL] [Abstract][Full Text] [Related]
15. Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA-sequencing and methylation modification data in endometrial cancer. Zhou H; Zhang Y; Jin J; Shen K; Yang Y; Lao P J Gene Med; 2024 Jan; 26(1):e3638. PubMed ID: 38011892 [TBL] [Abstract][Full Text] [Related]
16. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer. Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679 [TBL] [Abstract][Full Text] [Related]
17. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma. Wang G; Fu J; Liu M; Zheng Q PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115 [TBL] [Abstract][Full Text] [Related]
18. Identification of key transcription factors in endometrial cancer by systems bioinformatics analysis. Song Y; Chen QT; He QQ J Cell Biochem; 2019 Sep; 120(9):15443-15454. PubMed ID: 31037767 [TBL] [Abstract][Full Text] [Related]
19. Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools. Besso MJ; Montivero L; Lacunza E; Argibay MC; Abba M; Furlong LI; Colas E; Gil-Moreno A; Reventos J; Bello R; Vazquez-Levin MH Oncol Rep; 2020 Sep; 44(3):873-886. PubMed ID: 32705231 [TBL] [Abstract][Full Text] [Related]
20. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]